Impulse (Qingdao) Health TechLtd's (SZSE:002899) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Impulse (Qingdao) Health TechLtd's (SZSE:002899) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Impulse (Qingdao) Health Tech Co.,Ltd.'s (SZSE:002899) stock showed strength, with investors undeterred by its weak earnings report. Sometimes, shareholders are willing to ignore soft numbers with the hope that they will improve, but our analysis suggests this is unlikely for Impulse (Qingdao) Health TechLtd.
青岛思勉(Qingdao)保健科技有限公司(SZSE:002899)的股票显示出强劲的势头,投资者并不因其疲软的财报而动摇。有时,股东愿意忽略疲软的数字,希望它们会有所改善,但我们的分析表明,青岛思勉(Qingdao)保健科技有限公司可能不太可能出现这种情况。
To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. Impulse (Qingdao) Health TechLtd expanded the number of shares on issue by 22% over the last year. That means its earnings are split among a greater number of shares. To celebrate net income while ignoring dilution is like rejoicing because you have a single slice of a larger pizza, but ignoring the fact that the pizza is now cut into many more slices. Check out Impulse (Qingdao) Health TechLtd's historical EPS growth by clicking on this link.
要了解公司盈利增长的价值,有必要考虑股东权益的任何稀释。青岛思勉(Qingdao)保健科技有限公司在过去一年中将已发行股份数量扩大了22%。这意味着其盈利被分给了更多的股份。在忽略稀释的同时庆祝净利润,就好比因为你拥有更大的披萨饼的一块而欢欣,但却忽略了披萨饼现在被切成更多块。点击此链接查看青岛思勉(Qingdao)保健科技有限公司的历史每股收益增长。
A Look At The Impact Of Impulse (Qingdao) Health TechLtd's Dilution On Its Earnings Per Share (EPS)
审视青岛思勉(Qingdao)保健科技有限公司的稀释对其每股收益(EPS)的影响
As you can see above, Impulse (Qingdao) Health TechLtd has been growing its net income over the last few years, with an annualized gain of 153% over three years. But EPS was only up 136% per year, in the exact same period. Net income was down 5.4% over the last twelve months. Unfortunately for shareholders, though, the earnings per share result was even worse, declining 14%. So you can see that the dilution has had a bit of an impact on shareholders.
正如您所见,青岛思勉(Qingdao)保健科技有限公司在过去几年中一直在增加其净利润,年化增长率为153%。但在同一时期,每股收益仅增长了136%。净利润在过去十二个月中下降了5.4%。不幸的是,对于股东来说,每股收益的结果甚至更糟,下降了14%。因此,您可以看到股东受到了一定影响。
If Impulse (Qingdao) Health TechLtd's EPS can grow over time then that drastically improves the chances of the share price moving in the same direction. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.
如果青岛思勉(Qingdao)保健科技有限公司的每股收益可以随时间增长,那么股价沿着相同方向走的机会就会大大增加。然而,如果盈利增加而每股收益保持不变(甚至下降),那么股东可能不会看到太多好处。对于普通的零售股东来说,每股收益是一个很好的指标,可以检查您在公司盈利中的假想“份额”。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Impulse (Qingdao) Health TechLtd.
注:我们始终建议投资者检查资产负债表的实力。单击此处,查看青岛思勉(Qingdao)保健科技有限公司资产负债表分析。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
Alongside that dilution, it's also important to note that Impulse (Qingdao) Health TechLtd's profit was boosted by unusual items worth CN¥14m in the last twelve months. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If Impulse (Qingdao) Health TechLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
除了股权稀释,值得注意的是,青岛迅瑞康健康科技有限公司在过去十二个月中因价值1400万人民币的飞凡项目而获利增加。我们不能否认,利润增加通常会让我们感到乐观,但如果这种利润是可持续的,那将更好。当我们分析全球绝大多数上市公司时,我们发现重大的飞凡项目往往不会再次出现。毕竟,这正是会计术语所暗示的。如果青岛迅瑞康健康科技有限公司没有看到这种贡献再次出现,那么其他条件相同,我们预计其利润在当前年度会下降。
Our Take On Impulse (Qingdao) Health TechLtd's Profit Performance
我们对青岛迅瑞康健康科技有限公司的利润表现的看法
In its last report Impulse (Qingdao) Health TechLtd benefitted from unusual items which boosted its profit, which could make the profit seem better than it really is on a sustainable basis. And furthermore, it went and issued plenty of new shares, ensuring that each shareholder (who did not tip more money in) now owns a smaller proportion of the company. For the reasons mentioned above, we think that a perfunctory glance at Impulse (Qingdao) Health TechLtd's statutory profits might make it look better than it really is on an underlying level. So while earnings quality is important, it's equally important to consider the risks facing Impulse (Qingdao) Health TechLtd at this point in time. For example - Impulse (Qingdao) Health TechLtd has 1 warning sign we think you should be aware of.
在最近的报告中,青岛迅瑞康健康科技有限公司受益于飞凡项目,这些项目提升了其利润,这可能会使利润看起来比实际情况更好。此外,它还发行了大量新股,确保每位股东(未增加更多资金的股东)现在拥有的公司份额较小。出于上述原因,我们认为粗略查看青岛迅瑞康健康科技有限公司的法定利润可能使其看起来比实际情况更好。因此,尽管盈利质量很重要,但同样重要的是考虑青岛迅瑞康健康科技有限公司目前面临的风险。例如,青岛迅瑞康健康科技有限公司有1个警示标志,我们认为你应该意识到。
In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
在本文章中,我们研究了几个可能影响利润数据实用性的因素,我们对此持谨慎态度。但是,如果您能够将精力集中在细节上,就一定会发现更多。例如,许多人认为高股本回报是良好企业经济的指标,而其他人则喜欢"跟随资金"并寻找内部人员在购买的股票。因此,您可能希望查看这个高股本回报的免费收藏,或此具有高内部所有权的股票列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。